RU2616500C2 - Композиция пазопаниба - Google Patents

Композиция пазопаниба Download PDF

Info

Publication number
RU2616500C2
RU2616500C2 RU2014115289A RU2014115289A RU2616500C2 RU 2616500 C2 RU2616500 C2 RU 2616500C2 RU 2014115289 A RU2014115289 A RU 2014115289A RU 2014115289 A RU2014115289 A RU 2014115289A RU 2616500 C2 RU2616500 C2 RU 2616500C2
Authority
RU
Russia
Prior art keywords
composition
indazol
pyrimidinyl
methylamino
dimethyl
Prior art date
Application number
RU2014115289A
Other languages
English (en)
Russian (ru)
Other versions
RU2014115289A (ru
Inventor
Огастус Кэмпбелл ГОССЕТТ
Хелен РИЧАРДСОН
Питер А. УИЛЛЬЯМС
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2014115289A publication Critical patent/RU2014115289A/ru
Application granted granted Critical
Publication of RU2616500C2 publication Critical patent/RU2616500C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014115289A 2011-10-31 2012-10-16 Композиция пазопаниба RU2616500C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
US61/553,454 2011-10-31
PCT/US2012/060361 WO2013066616A1 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Publications (2)

Publication Number Publication Date
RU2014115289A RU2014115289A (ru) 2015-12-10
RU2616500C2 true RU2616500C2 (ru) 2017-04-17

Family

ID=48192602

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014115289A RU2616500C2 (ru) 2011-10-31 2012-10-16 Композиция пазопаниба

Country Status (12)

Country Link
US (3) US9278099B2 (enExample)
EP (1) EP2773204A4 (enExample)
JP (2) JP6200893B2 (enExample)
KR (1) KR101993436B1 (enExample)
CN (1) CN104254249B (enExample)
AU (1) AU2012332952B2 (enExample)
BR (1) BR112014010551A2 (enExample)
CA (1) CA2852912A1 (enExample)
HK (1) HK1201685A1 (enExample)
IN (1) IN2014CN02850A (enExample)
RU (1) RU2616500C2 (enExample)
WO (1) WO2013066616A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145157A1 (en) * 2014-03-28 2015-10-01 Cipla Limited Pharmaceutical composition comprising pazopanib
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
BR112020021059B1 (pt) 2018-04-24 2022-08-30 Shionogi & Co., Ltd Forma de dosagem sólida

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2241460C2 (ru) * 2001-11-23 2004-12-10 Глэксо Груп Лимитед Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом
RU2003130115A (ru) * 2003-10-14 2005-04-10 Федеральное государственное унитарное предпри тие "Всероссийкий научный центр по безопасности биологически активных веществ"(ФГУП "ВНЦ БАВ") (RU) Стабильная фармацевтическая суспензия азитромицина и способ ее получения
US20090005406A1 (en) * 2005-11-29 2009-01-01 Smithkline Beecham Corporation Cancer Treatment Method
RU2381223C2 (ru) * 2004-08-16 2010-02-10 Тереванс, Инк. Кристаллическая форма бифенильного соединения

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (enExample) 1988-03-25 1990-10-15 Ciba Geigy Ag
EP0373103B1 (de) 1988-11-10 1993-03-31 Ciba-Geigy Ag Flüssige orale Formulierung
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
EP1968594B1 (en) 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP2316422A1 (en) * 2007-11-12 2011-05-04 Novartis AG Liquid compositions comprising valsartan
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
US20100291025A1 (en) * 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2241460C2 (ru) * 2001-11-23 2004-12-10 Глэксо Груп Лимитед Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом
RU2003130115A (ru) * 2003-10-14 2005-04-10 Федеральное государственное унитарное предпри тие "Всероссийкий научный центр по безопасности биологически активных веществ"(ФГУП "ВНЦ БАВ") (RU) Стабильная фармацевтическая суспензия азитромицина и способ ее получения
RU2381223C2 (ru) * 2004-08-16 2010-02-10 Тереванс, Инк. Кристаллическая форма бифенильного соединения
US20090005406A1 (en) * 2005-11-29 2009-01-01 Smithkline Beecham Corporation Cancer Treatment Method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RU 2241460 C2, 12.2004. *

Also Published As

Publication number Publication date
KR20140096082A (ko) 2014-08-04
JP2017197542A (ja) 2017-11-02
RU2014115289A (ru) 2015-12-10
JP6200893B2 (ja) 2017-09-20
AU2012332952B2 (en) 2016-05-05
US20180360971A1 (en) 2018-12-20
HK1201685A1 (en) 2015-09-11
CA2852912A1 (en) 2013-05-10
US10596263B2 (en) 2020-03-24
CN104254249B (zh) 2017-02-15
CN104254249A (zh) 2014-12-31
WO2013066616A1 (en) 2013-05-10
US20160120988A1 (en) 2016-05-05
US20140255505A1 (en) 2014-09-11
EP2773204A1 (en) 2014-09-10
KR101993436B1 (ko) 2019-06-26
US9278099B2 (en) 2016-03-08
IN2014CN02850A (enExample) 2015-07-03
EP2773204A4 (en) 2015-05-27
JP6423484B2 (ja) 2018-11-14
US10080802B2 (en) 2018-09-25
AU2012332952A1 (en) 2014-05-15
BR112014010551A2 (pt) 2017-05-02
JP2014534215A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
JP4334869B2 (ja) 溶解性または経口吸収性の改善された組成物
US20170319484A1 (en) Diclofenac formulations and methods of use
JP5202856B2 (ja) トシル酸トスフロキサシンを含有する粒状固形製剤
WO2018142336A1 (en) Lamotrigine suspension dosage form
US10596263B2 (en) Pazopanib formulation
JP3518601B2 (ja) エバスタイムまたはその類似体に基づく医薬組成物
EP2005945B1 (en) Oseltamivir phosphate granule and preparation method thereof
WO2018071547A1 (en) Powder for oral suspension containing lamotrigine
US20020028794A1 (en) Megestrol acetate suspension
JP2005060265A (ja) ロラタジンを含むドライシロップ剤
US20240082160A1 (en) Amlodipine dry suspension and preparation method therefor
EP3806821B1 (en) Oral compositions comprising methylprednisolone sodium succinate
JP5799061B2 (ja) トスフロキサシンおよびポリビニルピロリドンを含有する粒状固形製剤
JP5799062B2 (ja) トスフロキサシンを含有する粒状固形製剤

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant